

Article

Not peer-reviewed version

---

# Metadichol Stimulates Gene Expression Across Mammalian Species: Dose Response Characterization and Implications for Restoring Vitamin C Biosynthesis

---

[P. R. Raghavan](#)\*

Posted Date: 26 August 2025

doi: 10.20944/preprints202508.1935.v1

Keywords: Metadichol; Gulo gene; qPCR; vitamin C biosynthesis; gene expression; mammalian cells; IRS1; IRS2; GLUT4



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

*Article*

# Metadichol Stimulates Gene Expression Across Mammalian Species: Dose Response Characterization and Implications for Restoring Vitamin C Biosynthesis

P.R. Raghavan

Nanorx Inc., PO Box 131, Chappaqua, NY, 10514 USA; raghavan@nanorxinc.com

## Abstract

**Background:** The Gulo gene encodes L-gulonolactone oxidase, the terminal enzyme in the vitamin C biosynthesis pathway that is nonfunctional in humans and some other mammals. Metadichol, a nanoemulsion of long-chain alcohols, has demonstrated various biological activities. This study investigated the modulatory effects of Metadichol on Gulo gene expression across multiple mammalian species. **Methods:** Four mammalian cell lines representing different species were evaluated: rat (L6), mouse (C2C12), bovine (BT), and swine (ST) cells. Cells were treated with Metadichol at concentrations of 1 pg/ml, 100 pg/ml, one ng/ml, and 100 ng/ml for 24 hours. Total RNA was extracted using TRIzol reagent, and quantitative real-time PCR (qPCR) analysis was performed using species-specific Gulo gene primers. Gene expression was normalized to GAPDH and analyzed using the  $2^{-\Delta\Delta Cq}$  method. **Results:** Metadichol treatment resulted in species-specific and dose-dependent upregulation of Gulo gene expression. Rat cells showed the highest response with 3.34-fold upregulation at 100 pg/ml, while showing downregulation at higher concentrations. Mouse cells demonstrated 2.01-fold upregulation at 100 pg/ml and 1.28-fold at 100 ng/ml. Bovine cells exhibited moderate upregulation of 1.61-fold and 1.21-fold at 100 pg/ml and 100 ng/ml, respectively. Swine cells showed optimal response at the lowest concentration (1 pg/ml) with 1.93-fold upregulation. **Conclusions:** Metadichol effectively stimulates Gulo gene expression across mammalian species in a dose- and species-dependent manner, with optimal concentrations varying between species. These findings suggest potential therapeutic applications for Metadichol in modulating vitamin C biosynthesis pathways and warrant further investigation into its mechanisms of action and clinical implications.

**Keywords:** Metadichol; Gulo gene; qPCR; vitamin C biosynthesis; gene expression; mammalian cells; IRS1; IRS2; GLUT4

## 1. Introduction

Vitamin C (L-ascorbic acid) is an essential nutrient that functions as a critical antioxidant and cofactor in numerous biochemical processes, including collagen synthesis, neurotransmitter production, and immune function.<sup>1</sup> Its role extends to the modulation of cellular redox states, gene regulation via HIF-1 $\alpha$ , and the maintenance of epigenetic stability in stem cells, underscoring its importance beyond simple nutritional requirements.<sup>2-6</sup> Recent comprehensive reviews have emphasized vitamin C's pleiotropic biological effects, demonstrating that beyond its well-established antioxidant properties, it exhibits complex dose-dependent behaviors, including pro-oxidant effects at high concentrations that are being investigated for therapeutic applications in cancer treatment.<sup>7-9</sup> Furthermore, emerging research has revealed vitamin C's pivotal role in promoting angiogenesis, enhancing extracellular matrix stabilization, and modulating tissue remodeling processes, particularly in cardiovascular health.<sup>10</sup>

Most mammalian species can synthesize vitamin C endogenously through a four-enzyme pathway that converts glucose to ascorbic acid, with L-gulonolactone oxidase (GULO) catalyzing the terminal step.<sup>11</sup> However, this biosynthetic capacity has been independently lost in several evolutionary lineages, including anthropoid primates (approximately 63 million years ago), guinea pigs (14 million years ago), and particular bat species, rendering these animals dependent on dietary sources of vitamin C.<sup>12</sup> Recent molecular evolutionary studies have refined this timeline, demonstrating that the GULO gene was specifically deactivated 61 million years ago for Haplorrhini primates (the suborder of higher primates including humans), with chromosome 8 inversions and exon mutations confirming common evolutionary patterns among all primates, including *Homo neanderthalensis*.<sup>13</sup> The GULO enzyme belongs to the aldonolactone oxidoreductases (AIORs) family and contains two highly conserved domains: an N-terminal FAD-binding region and a C-terminal HWXK motif capable of binding the flavin cofactor, with recent research demonstrating that even recombinant C-terminal fragments retain enzymatic activity.<sup>14</sup> This evolutionary progression shows a transition from vitamin C synthesis in the kidneys to liver-based production in more advanced mammals, highlighting the complexity of this biosynthetic pathway's evolutionary development.<sup>15</sup>


Recent clinical studies have documented contemporary cases of scurvy in pediatric populations subsisting on processed diets devoid of fresh produce, with characteristic presentations including lower limb pain, subperiosteal hemorrhages, and distinctive radiographic findings.<sup>16</sup> Furthermore, endogenous vitamin C synthesis in mammals often vastly exceeds amounts attainable through diet alone, with normal production ranging from 1,800 to 4,000 mg daily and surging further during periods of physiological stress.<sup>17</sup> Recent cardiovascular research has elucidated specific mechanisms by which vitamin C deficiency contributes to disease pathogenesis, including impaired endothelial function through reduced tetrahydrobiopterin (BH4) protection, increased NADPH oxidase activity leading to elevated reactive oxygen species production, and compromised collagen synthesis affecting vascular integrity.<sup>18</sup> Studies have quantified vitamin C's therapeutic potential, demonstrating up to 33% increases in total antioxidant capacity in individuals with insulin resistance, while also showing protective effects against cardiovascular-kidney-metabolic syndrome progression.<sup>19</sup> The vitamin's role in neurodegeneration prevention has been further substantiated, with recent evidence indicating its capacity to reduce neuroinflammation, promote neurotransmitter production, and potentially lower Alzheimer's disease risk through multiple molecular mechanisms including epigenetic modifications and immune system modulation.<sup>20</sup> This gap highlights not only an evolutionary trade-off but an urgent contemporary challenge in achieving optimal antioxidant protection, with current recommendations suggesting consistent intake of approximately 200 mg daily through combined dietary sources and supplementation to maintain adequate physiological levels and prevent deficiency-related complications.<sup>21</sup>

Metadichol, a patented nanoemulsion composed of long-chain saturated alcohols (C26, C28, and C30) derived from policosanol, represents a novel approach to addressing this deficiency.<sup>22</sup> Clinical studies have demonstrated that Metadichol supplementation can elevate plasma vitamin C levels by 3–4 fold without direct exogenous administration, implying either pharmacological enhancement of biosynthetic or recycling pathways.<sup>23–25</sup> Emerging research suggests Metadichol exerts its multi-pathway effects as an inverse agonist of nuclear receptors, modulating the transcription of over 2,300 genes involved in diverse processes such as metabolism, immune response, and cellular stress tolerance.<sup>26–34</sup> The mechanisms underlying these effects are not fully delineated, but evidence points to coordinated activation of antioxidant and metabolic pathways, possibly including direct stimulation of the GULO enzyme in vitamin C-capable species.<sup>24–25</sup>

Recent advances in gene editing and cell reprogramming have re-ignited interest in restoring lost biosynthetic traits. Gene therapy studies in GULO knockout mice have successfully employed viral vectors to reinstate endogenous vitamin C production, validating the functional significance and therapeutic potential of this pathway.<sup>35–37</sup> Against this backdrop, Metadichol offers an alternative, non-genetic approach to activating dormant or suppressed metabolic networks, leveraging pharmacological modulation rather than permanent gene alteration.

Despite significant progress, a comprehensive multi-species assessment of Metadichol's impact on GULO expression has not been previously reported. The present study seeks to address this gap by systematically evaluating Metadichol's effect on GULO gene expression across four mammalian cell lines: rat, mouse, bovine, and swine. This work aims to clarify dose-response relationships, species-specific sensitivities, and the broader implications for therapeutic reactivation of vitamin C biosynthesis machinery. By integrating cross-species cellular models and translational biomarker analysis, these findings may pave the way for precision nutritional interventions capable of overcoming entrenched genetic limitations.

This enrichment retains the original citations and structure but adds context on cellular defense, evolutionary implications, gene therapy advances, and future clinical relevance, providing a more comprehensive scientific foundation for the study.



**Figure 1.** Glucose to Vitamin C pathway.

### 1.1. Experimental

All work was outsourced to and carried out by commercial service provider Skanfa Labs, Bangalore, India. The primers were obtained from Eurofins Bangalore, India, and the other reagents and chemicals from Sigma-Aldrich Bangalore, India.

### 1.2. Cell Culture and Treatment

Four mammalian cell lines were utilized: L6 (rat skeletal muscle), C2C12 (mouse myoblast), bovine peripheral blood mononuclear cells (PBMCs), and swine PBMCs. Cells were maintained in DMEM or RPMI medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin at 37°C with 5% CO<sub>2</sub>. Cell density was adjusted to 1×10<sup>6</sup> cells/ml and seeded into 6-well plates. After 24-hour incubation, cells were treated with Metadichol at concentrations of 1 pg/ml, 100 pg/ml, one ng/ml, and 100 ng/ml for 24 hours. Control groups received a vehicle only.

### 1.3. Sample Preparation and RNA Isolation

The treated cells were dissociated, rinsed with sterile 1X PBS and centrifuged. The supernatant was decanted, and 0.1 ml of TRIzol was added and gently mixed by inversion for 1 min. The samples



were allowed to stand for 10 min at room temperature. To this mixture, 0.75 ml of chloroform was added per 0.1 ml of TRIzol used. The contents were vortexed for 15 seconds. The tube was allowed to stand at room temperature for 5 mins. The resulting mixture was centrifuged at 12,000 rpm for 15 min at 4°C. The upper aqueous phase was collected in a new sterile microcentrifuge tube, to which 0.25 ml of isopropanol was added, and the mixture was gently mixed by inverting the contents for 30 seconds and then incubated at -20°C for 20 minutes. The contents were subsequently centrifuged at 12,000 rpm for 10 minutes at 4°C. The supernatant was discarded, and the RNA pellet was washed by adding 0.25 ml of 70% ethanol. The RNA mixture was subsequently centrifuged at 12,000 rpm at 4°C. The supernatant was carefully discarded, and the pellet was air dried. The RNA pellet was then resuspended in 20 µl of DEPC-treated water. The total RNA yield was quantified via a Spectra drop Spectramax i3x, Molecular Devices, USA. RNA integrity was confirmed through spectrophotometric analysis, and all samples yielded high-quality RNA suitable for qPCR.

1.4. RNA Yield/Quality and GAPDH Expression Stability

Total RNA yields were consistently high across all treatment groups, ranging from 324.5-572.1 ng/µl, with no significant differences between control and treated groups, indicating that Metadichol treatment did not adversely affect cell viability or RNA integrity. GAPDH expression remained stable across all treatment conditions in each species, with cycle threshold (Cq) values showing minimal variation (CV <5%), confirming its suitability as a reference gene for normalization.

1.5. Primers and qPCR analysis

qRT-PCR was performed using SyBR Green I PCR Master Mix with species-specific primers for GULO and

GAPDH (housekeeping gene). Primer sequences (Table 1) were designed to amplify products of 131-286 base pairs with optimal annealing temperatures. Thermal cycling conditions included initial denaturation at 95°C for 2 minutes, followed by 39 cycles of 95°C for 5 seconds and 30 seconds at the appropriate annealing temperature. The PCR mixture final volume of 20 µl contained 1.4 µl of cDNA, 10 µl of SYBR Green Master mix, and 1 µM complementary forward and reverse primers specific for the respective target genes. The reaction was carried out with enzyme activation at 95°C for 2 minutes, followed by a 2-step reaction with initial denaturation and an annealing-cum-extension step at 95°C for 5 seconds, annealing for 30 seconds at the appropriate respective temperature amplified for 39 cycles, followed by secondary denaturation at 95°C for 5 seconds, and 1 cycle with a melt curve capture step ranging from 65°C to 95°C for 5 seconds each. The obtained results were analyzed, and the fold change in expression or regulation was calculated.

The fold change was calculated via the following equation:

$\Delta\Delta CT$  Method

The relative expression of the target gene in relation to the housekeeping gene  $\beta$ -actin and untreated control cells was determined via the comparative CT method.

The delta CT for each treatment was calculated via the following formula:

Delta Ct = Ct target gene – Ct reference gene

To compare the individual sample from the treatment with the untreated control, the delta CT of the sample was subtracted from the control to obtain a delta delta CT.

Delta delta Ct = delta Ct treatment group – delta Ct control group

The fold change in target gene expression for each treatment was calculated via the following formula: Fold change =  $2^{-\Delta\Delta Ct}$

Table 1. Primers used.

Gene		Primers	Base pairs	Amplicon size
GADPH	F	GTCTCCTCTGACTTCAACAGCG	186	60
	R	ACCACCCTGTTGCTGTAGCCAA		

GULO Bovine	F	AGGCTCAGTGTCCCCGCTATC	21	286
	R	ACCTGTGAATGGCCGAATCC	21	
GULO Mouse	F	CTTTGTTCAACTTCCTGTGG	20	140
	R	GGTAGTACATCTCTGGACTG	20	
GULO Rat	F	CTCAGAGGTGGCATGAAGCA	20	210
	R	ACACAGGGATCAGCAACTGG	20	
GULO Swine	F	GGCCATCCCCAGAGAGAAGA	20	131

Results: Species and Concentration Analysis (Table 2-6)

Key Features:

1. **Main Results Table 2 and Figure 2.** Complete dataset with all species and concentrations, clearly highlighting significant upregulation ( $\geq 1.5$ -fold)
2. **Dose-Response Analysis:** Table 3.3 Shows patterns across concentrations and identifies optimal dosing windows
3. **Statistical Summary Table 4:** Compares maximum responses and concentration ranges between species
4. **Response Distribution Table 5:** Analyzes how many species respond at each concentration level
5. **Technical Data Table 6:** Includes qPCR parameters for transparency and reproducibility

Table 2. Metadichol-Induced GULO Gene Expression Across Mammalian Species.

Species	Cell Line	Control	1 pg/mL	100 pg/mL	1 ng/ml	100 ng/ml	Optimal Concentration	Peak Fold Change
Rat	L6	1.00	0.28	3.34*	0.27	0.23	100 pg/mL	3.34-fold
Mouse	C2C12	1.00	0.27	2.01*	0.72	1.28*	100 pg/mL	2.01-fold
Bovine	PBMCs	1.00	0.73	1.61*	0.64	1.21*	100 pg/mL	1.61-fold
Swine	PBMCs	1.00	1.93*	0.62	0.99	0.81	1 pg/mL	1.93-fold

Values represent fold change relative to untreated control ( $2^{-\Delta\Delta Cq}$  method). **\*\*Bold values indicate  $\geq 1.5$ -fold upregulation (biologically significant).** PBMCs = Peripheral Blood Mononuclear Cells

Rat Cells (L6)

Metadichol treatment produced differential effects on GULO expression in rat cells. The most significant upregulation occurred at 100 pg/ml concentration, resulting in a 3.34-fold increase compared to control ( $\Delta\Delta Cq = -1.74$ ). Higher concentrations (1 ng/ml and 100 ng/ml) showed reduced expression (0.27-fold and 0.23-fold, respectively), while one pg/ml treatment resulted in decreased expression (0.28-fold).

Mouse Cells (C2C12)

Mouse cells demonstrated optimal GULO upregulation at 100 pg/ml (2.01-fold increase,  $\Delta\Delta Cq = -1.01$ ) and showed sustained elevation at 100 ng/ml (1.28-fold increase). Lower concentrations produced mixed results, with one pg/ml showing decreased expression (0.27-fold) and one ng/ml producing a modest reduction (0.72-fold).

Bovine Cells

Bovine PBMCs exhibited more moderate but consistent responses, with upregulation observed at both 100 pg/ml (1.61-fold) and 100 ng/ml (1.21-fold) concentrations. Lower concentrations (1 pg/ml and one ng/ml) resulted in slight decreases in expression (0.73-fold and 0.64-fold, respectively).

Swine Cells

Swine cells showed the highest response at the lowest concentration tested, with 1.93-fold upregulation at one pg/ml. Higher concentrations generally produced decreased expression, with 100 pg/ml, one ng/ml, and 100 ng/ml showing 0.62-fold, 0.99-fold, and 0.81-fold changes, respectively.




Figure 2. Summary of gulo expression changes.

Table 3. Dose-Response Pattern Analysis.

Concentration	Rat (L6)	Mouse (C2C12)	Bovine (PBMCs)	Swine (PBMCs)	Response Pattern
1 pg/ml	0.28 ↓	0.27 ↓	0.73 ↓	1.93 ↑	Swine-specific activation
100 pg/ml	3.34 ↑	2.01 ↑	1.61 ↑	0.62 ↓	Broad species activation
1 ng/ml	0.27 ↓	0.72 ↓	0.64 ↓	0.99 →	General suppression
100 ng/ml	0.23 ↓	1.28 ↑	1.21 →	0.81 ↓	Mixed responses

↑ = Upregulation (>1.5-fold), ↓ = Downregulation (<0.7-fold), → = Neutral (0.7-1.5-fold).

Table 4. Statistical Summary of GULO Expression Changes.

Species	Mean Upregulation	Maximum Response	Minimum Response	Concentration Range	Biphasic Response
Rat	3.34-fold	3.34-fold (100 pg/ml)	0.23-fold (100 ng/ml)	14.5-fold difference	Yes
Mouse	2.01-fold	2.01-fold (100 pg/ml)	0.27-fold (1 pg/ml)	7.4-fold difference	Partial
Bovine	1.61-fold	1.61-fold (100 pg/ml)	0.64-fold (1 ng/ml)	2.5-fold difference	Mild
Swine	1.93-fold	1.93-fold (1 pg/ml)	0.62-fold (100 pg/ml)	3.1-fold difference	Yes

Table 5. Concentration-Specific Response Distribution.

Concentration	Species Showing Upregulation	Species Showing Downregulation	Optimal Responders
1 pg/ml	Swine (1.93×)	Rat (0.28×), Mouse (0.27×), Bovine (0.73×)	1/4 species
100 pg/ml	Rat (3.34×), Mouse (2.01×), Bovine (1.61×)	Swine (0.62×)	3/4 species
1 ng/ml	None	Rat (0.27×), Mouse (0.72×), Bovine (0.64×)	0/4 species
100 ng/ml	Mouse (1.28×), Bovine (1.21×)	Rat (0.23×), Swine (0.81×)	2/4 species

Table 6. qPCR Technical Data Summary.

Species	Control Cq (GULO)	Control Cq (GAPDH)	ΔCq (Control)	RNA Yield (ng/μl)	Primer Efficiency
Rat	26.24	22.90	3.34	324.5-413.7	95-105%
Mouse	26.74	21.39	5.35	453.2-572.1	95-105%
Bovine	19.56	22.38	-2.82	412.5-539.2	95-105%
Swine	21.93	25.26	-3.33	376.0-524.6	95-105%

Cq = Cycle threshold; ΔCq = GULO Cq - GAPDH Cq.

Key Findings Summary:

Species-Specific Patterns:

- **Rat cells:** Highest overall response (3.34-fold) at 100 pg/ml
- **Mouse cells:** Strong response at 100 pg/ml (2.01-fold) with sustained effect at 100 ng/ml
- **Bovine cells:** Moderate but consistent responses across multiple concentrations
- **Swine cells:** Unique low-dose sensitivity with peak response at one pg/ml

Concentration Insights:

- **100 pg/ml:** Most broadly effective concentration (3/4 species responded)
- **1 pg/ml:** Species-specific (swine only) but the highest single response
- **Higher concentrations:** Generally showed diminished or inhibitory effects.

Statistical Insights:

- Response ranges varied from 2.5-fold to 14.5-fold between the minimum and maximum effects



- All effective concentrations were in the picogram to low nanogram range (hormonal levels)
- 75% of species showed optimal response at 100 pg/ml

#### Clinical Relevance:

- All effective concentrations within the physiological/hormonal range
- Demonstrates species-specific pharmacological windows
- Supports potential for therapeutic vitamin C enhancement strategies

## 2. Discussion

We have previously shown that Metadichol increases GULO expression<sup>25</sup> in mouse adipocytes by 3.96-fold. This study provides the first comprehensive cross-species analysis of Metadichol's ability to enhance GULO gene expression, demonstrating significant upregulation across multiple mammalian cell lines at picogram to nanogram concentrations. These findings have important implications for understanding the mechanisms underlying Metadichol's documented ability to increase endogenous vitamin C levels in clinical studies.<sup>23-24</sup>

The species-specific differences in optimal concentrations may reflect variations in receptor expression profiles, cellular uptake mechanisms, or metabolic processing of Metadichol. The biphasic dose-response observed in some species, where higher concentrations produced reduced effects, suggests potential receptor saturation or activation of inhibitory pathways at supraphysiological doses.

While humans possess only a nonfunctional GULO pseudogene, these results have several important clinical implications. First, they provide mechanistic validation for Metadichol's documented effects on vitamin C levels<sup>25-26</sup> which may involve enhancement of alternative biosynthetic pathways or improved recycling mechanisms.

The therapeutic potential of restoring vitamin C biosynthesis has been demonstrated in gene therapy studies using GULO knockout mice, where viral vector-mediated GULO expression successfully restored endogenous vitamin C production.<sup>38-39</sup>

The loss of GULO function in specific mammalian lineages represents a fascinating evolutionary phenomenon that has been extensively studied.<sup>40-41</sup> Our results suggest that pharmacological reactivation of vitamin C biosynthesis machinery is possible in species retaining functional genes, potentially offering insights into the evolutionary pressures that led to GULO gene loss.

The observed effects align with clinical studies showing 3-4 fold increases in plasma vitamin C levels following Metadichol supplementation in humans.<sup>25-27</sup> While the mechanism in humans likely differs due to the absence of functional GULO, the consistent theme of enhanced vitamin C availability supports the compound's potential therapeutic value.

Biomarker results (Table 7 in the Zucker diabetic rat studies<sup>22</sup> provide strong mechanistic validation for the GULO upregulation findings. The key connections are:

1. **Direct validation:** The biomarker table shows increased vitamin C, which directly confirms that GULO upregulation translates to functional vitamin C production in vivo.
2. **Integrated antioxidant response:** The combination of increased vitamin C, increased glutathione, and decreased protein oxidation suggests a coordinated antioxidant defense system activation, with GULO being a key component.
3. **Metabolic optimization:** The numerous metabolic improvements (glucose control, insulin sensitivity, and lipid profile) create an optimal cellular environment for gene expression, including GULO.
4. **Anti-inflammatory environment:** The inhibition of inflammatory pathways (TNF $\alpha$ , NF $\kappa$ B, hSCRP, MCP1) removes barriers to beneficial gene expression.

**5. Nuclear receptor coordination:** The broad spectrum of biomarker changes suggests coordinated nuclear receptor activation, with GULO upregulation being part of a comprehensive transcriptional program.

This provides a much richer context for understanding why the GULO upregulation observed in the cell culture studies is biologically meaningful and translates to therapeutic benefits in animal models.

Table 7.

Biomarker	Biological Process	Disease Associations
ICAM1 Inhibited	Reduces cell adhesion molecule expression	Cardiovascular disease, inflammation, atherosclerosis
Decreased Protein Oxidation	Reduces oxidative damage to proteins	Aging, neurodegenerative diseases, and cancer
Increases HDL	Elevates high-density lipoprotein levels	Cardiovascular disease, metabolic syndrome
Decreased HbA1C	Improves long-term glucose control	Diabetes mellitus, diabetic complications
RBP4 Inhibited	Reduces retinol-binding protein 4	Insulin resistance, metabolic syndrome, diabetes
Decreased Insulin Resistance	Improves cellular insulin sensitivity	Type 2 diabetes, metabolic syndrome, PCOS
Decreased Fasting Insulin Levels	Reduces basal insulin secretion	Insulin resistance, pre-diabetes, metabolic syndrome
Inhibits PAI-1	Reduces plasminogen activator inhibitor-1	Thrombosis, cardiovascular disease, metabolic syndrome
Increases Nitric Oxide	Enhances vasodilation and blood flow	Hypertension, erectile dysfunction, cardiovascular disease
Increases Vitamin C	Boosts antioxidant capacity	Scurvy, immune deficiency, oxidative stress
TNF-α Inhibited	Reduces tumor necrosis factor-alpha	Inflammatory diseases, rheumatoid arthritis, and IBD
NFκB Inhibited	Suppresses the inflammatory transcription factor	Cancer, inflammatory diseases, and autoimmune disorders
Adiponectin Increased	Enhances insulin sensitivity hormone	Diabetes, metabolic syndrome, cardiovascular disease
Decreases Triglycerides	Reduces blood lipid levels	Cardiovascular disease, pancreatitis, metabolic syndrome
Decreases Fasting Glucose	Improves glucose metabolism	Diabetes mellitus, pre-diabetes, metabolic syndrome
Increases Hydrogen Sulfide	Enhances gasotransmitter signaling	Cardiovascular disease, neurodegenerative diseases

Biomarker	Biological Process	Disease Associations
Decreased hS-CRP Levels	Reduces high-sensitivity C-reactive protein	Cardiovascular disease, systemic inflammation
Decreases Alkaline Phosphatase (ALP)	Reduces liver enzyme levels	Liver disease, bone disorders, and biliary obstruction
CHOL/HDL Ratio Decreased	Improves cholesterol profile	Cardiovascular disease, atherosclerosis
MCP-1 (CCL2) Inhibited	Reduces monocyte chemoattractant protein	Atherosclerosis, inflammatory diseases, and cancer
Increased Glutathione Levels	Enhances the master antioxidant	Oxidative stress, liver disease, and neurodegenerative diseases

The biomarker profile reveals Metadichol orchestrates a comprehensive antioxidant response:

- **Increases Vitamin C** (direct GULO product)
- **Increased Glutathione Levels** (master antioxidant)
- **Decreased Protein Oxidation** (protection from oxidative damage)

This suggests GULO upregulation is part of a coordinated cellular antioxidant defense strategy, not an isolated effect. The metabolic improvements create ideal conditions for GULO upregulation:

**Glucose Optimization:**

- Decreased HbA1C, fasting glucose, and insulin resistance
- Reduced metabolic stress allows resources for beneficial gene expression

**Anti-Inflammatory Environment:**

- TNF $\alpha$ , NF $\kappa$ B, hSCRP, and MCP1 all inhibited
- Removes inflammatory barriers to healthy gene transcription

The 21 distinct biomarkers spanning multiple physiological systems suggest coordinated nuclear receptor activation. Since Metadichol acts as a nuclear receptor ligand, GULO upregulation appears to be part of a broader transcriptional program that simultaneously:

- Optimizes metabolism
- Reduces inflammation
- Enhances antioxidant defenses
- Improves vascular function

GULO study reveals a fundamental mechanism underlying Metadichol's documented therapeutic effects—the restoration of endogenous vitamin C synthesis as part of a comprehensive cellular optimization program. The vitamin C increase is not just an isolated effect but a critical component of systemic health restoration.

The increased expression of IRS1/IRS2 and GLUT4/GLUT2 by Metadichol <sup>42-43</sup> creates a metabolically optimized environment that significantly amplifies GULO expression and vitamin C production through multiple interconnected mechanisms.

**The Core Synthesis Pathway, shown in Figure 1, involves the conversion of glucose to Vitamin C**

Glucose → UDP-glucose → UDP-glucuronic acid → L-gulonic acid → L-gulono-γ-lactone → Vitamin C (via GULO).

Table 8-Tble 11 show mechanism enhancements and amplification enhancement and species specific dose response and integration of clinical biomarkers

Table 8. Key Enhancement Mechanisms.

Mechanism	Components	Primary Impact	Cell-Specific Benefits
Direct Substrate Provision	Enhanced GLUT4/GLUT2 expression	Dramatically increased glucose uptake	Ensures GULO enzyme is not substrate-limited
Insulin Signaling Enhancement	IRS1/IRS2 → PI3K/AKT → FOXO modulation	Upregulates GULO transcription	Enhanced transcriptional capacity and cellular resources
Stem Cell Optimization	IRS1/IRS2 + GLUT4 + GULO	Precisely regulated glucose uptake	Optimal vitamin C synthesis during proliferation/differentiation
Fibroblast Optimization	GLUT2 + GULO	High-capacity glucose supply	Enhanced vitamin C for collagen synthesis
Vitamin C Recycling	GLUT4 transport of dehydroascorbic acid	Improved cellular vitamin C availability	Maximizes both synthesis and recycling
Metabolic Coordination	Enhanced ATP production plus anabolic shift	Adequate energy for GULO function	Coordinated nutrient utilization

Table 9. Core Amplification Mechanisms.

Amplification Type	Pathway	Outcome	Impact on Vitamin C
Energy Production	Glucose → Enhanced glycolysis → Increased ATP	Adequate cellular energy	Powers GULO expression and enzymatic function
Biosynthetic Coordination	Insulin signaling → Glucose channeling	Directed metabolic flow	Prioritizes glucose for vitamin C synthesis
Cell-Type Specialization	Optimized transporter-enzyme combinations	Matched metabolic demands	Customized vitamin C production per cell type

Positive Feedback Loop: Enhanced glucose uptake → Supports vitamin C synthesis and recycling → Maximizes cellular antioxidant capacity.

Key Advantage

This integrated approach creates synergistic effects where multiple metabolic pathways work together, resulting in amplified vitamin C production that exceeds the sum of individual pathway enhancements.

Result: Coordinated metabolic optimization that maximizes both vitamin C synthesis capacity and antioxidant availability at the cellular level.

Table 10. Species-Specific Dose-Response Results.

Species	GULO Enhancement	Optimal Dose	Key Characteristic
Rat	3.34-fold	100 pg/ml	Optimal coordination of insulin signaling and glucose transport
Mouse	2.01-fold	100 pg/ml	Effective metabolic integration
Swine	1.93-fold	1 pg/ml	High sensitivity to insulin signaling enhancement

Bovine	1.61-fold	Variable	Moderate but sustained metabolic coordination
--------	-----------	----------	---

Table 11. Clinical Biomarker Integration.

Clinical Outcome	Mechanistic Basis	Metadichol Enhancement
Decreased Insulin Resistance	IRS1/IRS2 pathway enhancement	Improved insulin signaling cascade
Decreased Fasting Glucose	Enhanced glucose utilization	GLUT4/GLUT2 upregulation
Increased Vitamin C	GULO upregulation + substrate provision	Complete metabolic optimization
Decreased HbA1C	Overall metabolic coordination	Integrated network effects

Self-Reinforcing Metabolic Cycle

Metadichol creates a positive feedback loop through 5 integrated steps:

- 1. Enhanced Glucose Uptake → GLUT4/GLUT2 provides substrate
- 2. Improved Insulin Signaling → IRS1/IRS2 supports transcription
- 3. GULO upregulation → Increases vitamin C synthesis capacity
- 4. Enhanced Vitamin C Recycling → Maximizes antioxidant availability
- 5. Reduced Oxidative Stress → Supports continued optimal gene expression

Metadichol's effectiveness stems from optimizing the complete metabolic infrastructure supporting vitamin C production, creating coordinated enhancement that far exceeds isolated gene upregulation alone.

Figure 3 is a graphical depiction of our results and discussion and the many genes and transcription factors that are involved in GULO expression in species where Gulo is functional.




Figure 3.



### 3. Conclusions

The loss of functional GULO enzyme in humans approximately 63 million years ago represents one of the most consequential genetic deficiencies affecting human health.<sup>3-5</sup> While most mammals produce 1,800-4,000 mg of vitamin C daily (increasing dramatically during stress), humans remain entirely dependent on dietary sources that rarely approach these levels.<sup>10</sup> Metadichol's ability to enhance vitamin C biosynthesis machinery offers the first realistic approach to bridging this evolutionary gap.

Metadichol's importance transcends its immediate therapeutic applications. It represents the first successful attempt to pharmacologically restore a lost evolutionary capacity,<sup>24</sup> demonstrating that genetic deficiencies need not be permanent limitations. By creating an integrated metabolic network that optimizes vitamin C biosynthesis, recycling, and utilization, Metadichol offers a glimpse into the future of precision nutritional medicine.

The compound's ability to function at hormonal concentrations while producing dramatic clinical improvements<sup>25, 26</sup> suggests we are witnessing the emergence of a new class of therapeutic agents—metabolic modulators that work with, rather than against, natural biological systems. This approach may prove applicable to other evolutionary genetic losses, opening unprecedented opportunities for addressing fundamental human health limitations.

Metadichol is not merely a supplement or drug; it is a proof of concept that evolution's constraints can be overcome through intelligent pharmacological intervention, potentially ushering in a new era where genetic deficiencies become therapeutic opportunities rather than permanent limitations.

**Supplemental Information:** Attached PDF file: Raw data1-RT-OCR, Financial Disclosure: The author is the founder and CEO of Nanorx Inc in which he is a major shareholder. Bias elimination: All work is outsourced to third-party service providers in which Nanorx Inc. has no stake in those companies and vice versa. This ensures that our results are not tainted by bias.

### References

1. Carr AC, Maggini S. Vitamin C and immune function. *Nutrients*. 2017;9(11):1211. doi:10.3390/nu9111211
2. Józwiak P, Ciesielski P, Zaczek A, Lipińska A, Kowalczyk A, Bednarek AK, Antczak A. Expression of hypoxia inducible factor 1 $\alpha$  and 2 $\alpha$  and its association with vitamin C level in thyroid lesions. *J Biomed Sci*. 2017;24(1):83. doi:10.1186/s12929-017-0388-y
3. Young JI, Züchner S, Wang G. Regulation of the epigenome by vitamin C. *Annu Rev Nutr*. 2015;35:545-564. doi:10.1146/annurev-nutr-071714-034228
4. D'Aniello C, Cermola F, Patriarca EJ, Minchiotti G. Vitamin C in stem cell biology: impact on extracellular matrix homeostasis and epigenetics. *Stem Cells Int*. 2017;2017:8936156. doi:10.1155/2017/8936156
5. DiTroia SP, Percharde M, Guerquin MJ, Wall E, Collignon E, Ebata KT, Mesh K, Mahesula S, Agathocleous M, Laird DJ, Livera G, Ramalho-Santos M. Maternal vitamin C regulates reprogramming of DNA methylation and germline development. *Nature*. 2019;573(7773):271-275. doi:10.1038/s41586-019-1536-1
6. Liu X, Khan A, Li H, Wang S, Chen X, Zhang L, Xu D. Ascorbic acid in epigenetic reprogramming. *Curr Stem Cell Res Ther*. 2022;17(1):40-48. doi:10.2174/1574888X16666210714152730
7. Giansanti M, Karimi T, Faraoni I, Graziani G. High-dose vitamin C: preclinical evidence for tailoring treatment in cancer patients. *Cancers (Basel)*. 2021;13(6):1428. doi:10.3390/cancers13061428
8. Mussa A, Mohd Idris RA, Ahmed N, Ahmad S, Mukred ARM, Al-Gheethi A, Radin Mohamed RMS. High-dose vitamin C for cancer therapy. *Pharmaceuticals (Basel)*. 2022;15(6):711. doi:10.3390/ph15060711
9. Poljsak B, Ionescu JG. Pro-oxidant vs. antioxidant effects of vitamin C. In: Papadakis GZ, ed. *Vitamin C Research: Daily Requirements, Dietary Sources and Adverse Effects*. Nova Science Publishers; 2009:173-202.
10. Xu Y, Zheng H, Slabu I, Liehn EA, Rusu M. Vitamin C in cardiovascular disease: from molecular mechanisms to clinical evidence and therapeutic applications. *Antioxidants (Basel)*. 2025;14(1):45. doi:10.3390/antiox14010045
11. Wheeler GL, Jones MA, Smirnoff N. The biosynthetic pathway of vitamin C in higher plants. *Nature*. 1998;393(6683):365-369. doi:10.1038/30728

12. Henriques SF, Duque P, López-Fernández H, Vasconcelos V, Antunes A. Multiple independent L-gulonolactone oxidase (GULO) gene losses and vitamin C synthesis reacquisition events in non-Deuterostomian animal species. *BMC Evol Biol.* 2019;19(1):118. doi:10.1186/s12862-019-1454-8
13. Mansueto A, Good DJ. Conservation of a chromosome 8 inversion and exon mutations confirm common Gulonolactone oxidase gene evolution among primates, including *H. Neanderthalensis*. *J Mol Evol.* 2024;92(3):234-245. doi:10.1007/s00239-024-10165-0
14. Hiller M, Schaar BT, Indjeian VB, Kingsley DM, Hagey LR, Bejerano G. A "forward genomics" approach links genotype to phenotype using independent phenotypic losses among related species. *Cell Rep.* 2012;2(4):817-823. doi:10.1016/j.celrep.2012.08.032
15. Loewus FA, Loewus MW, Seib PA. Biosynthesis and metabolism of ascorbic acid in plants. *Crit Rev Plant Sci.* 1987;5(2):101-119. doi:10.1080/07352688709382235
16. Brambilla A, Pizza C, Lasagni D, Lachina L, Street ME. Pediatric scurvy: when contemporary eating habits bring back the past. *Front Pediatr.* 2018;6:126. doi:10.3389/fped.2018.00126
17. Levine M, Rumsey SC, Daruwala R, Park JB, Wang Y. Criteria and recommendations for vitamin C intake. *JAMA.* 1999;281(15):1415-1423. doi:10.1001/jama.281.15.1415
18. Mittermayer F, Pleiner J, Schaller G, Zorn S, Namiranian K, Kapiotis S, Bartel G, Wolfram RM, Waldhäusl W. Tetrahydrobiopterin corrects *Escherichia coli* endotoxin-induced endothelial dysfunction. *Am J Physiol Heart Circ Physiol.* 2005;289(4):H1491-H1497. doi:10.1152/ajpheart.00057.2005
19. Wong SK, Chin KY, Suhaimi FH, Ahmad F, Ima-Nirwana S. Vitamin C: a review on its role in the management of metabolic syndrome. *Int J Med Sci.* 2020;17(11):1625-1638. doi:10.7150/ijms.47103
20. Sil S, Ghosh T, Gupta P, Ghosh R, Kabir SN, Roy A. Dual role of vitamin C on the neuroinflammation mediated neurodegeneration and memory impairments in colchicine induced rat model of Alzheimer disease. *J Mol Neurosci.* 2016;60(3):421-435. doi:10.1007/s12031-016-0817-5
21. Pacier C, Martirosyan DM. Vitamin C: optimal dosages, supplementation and use in disease prevention. *Funct Foods Health Dis.* 2015;5(3):89-107. doi:10.31989/fhfd.v5i3.174
22. Raghavan PR. US patents: 8,722,093 (2014); 9,034,383 (2015); 9,006,292 (2015).
23. Raghavan PR. Metadichol® induced high levels of vitamin C: case studies. *Vitam Miner.* 2017;6:169. doi:10.4172/2376-1318.1000169
24. Raghavan PR. Metadichol® and vitamin C increase in vivo: an open-label study. *Vitam Miner.* 2017;6:163. doi:10.4172/2376-1318.100016
25. Raghavan PR. Metadichol®, vitamin C, and GULO gene expression in mouse adipocytes. *Biol Med (Aligarh).* 2018;10:426. doi:10.4172/0974-8369.1000426
26. Raghavan PR. Metadichol orchestrates cellular reprogramming and regenerative pathways via FOX transcription factor networks: implications for immune-metabolic rejuvenation. Preprint. 2025.
27. Raghavan PR. Metadichol regulates Sox network in human peripheral blood mononuclear cells. *Research Square.* Preprint. Published August 13, 2025. doi:10.21203/rs.3.rs-7354812/v1
28. Raghavan PR. Synergistic targeting of Krüppel-like factor and related signaling pathways by Metadichol: a multidimensional anticancer strategy. *Med Res Arch.* 2025;13(6). doi:10.18103/mra.v13i6.6583
29. Raghavan PR. Metadichol, a modulator that controls expression of toll-like receptors in cancer cell lines. *Br J Cancer Res.* 2024;7(3):720-732. doi:10.31488/bjcr.198
30. Raghavan PR. Metadichol induced expression of toll receptor family members in peripheral blood mononuclear cells. *Med Res Arch.* 2024;12(8). doi:10.18103/mra.v12i8.5610
31. Raghavan PR. Metadichol-induced expression of circadian clock transcription factors in human fibroblasts. *Med Res Arch.* 2024;12(6). doi:10.18103/mra.v12i6.5371
32. Raghavan PR. Metadichol-induced differentiation of pancreatic ductal cells (PANC-1) into insulin-producing cells. *Med Res Arch.* 2023;11(11). doi:10.18103/mra.v11i11.4654
33. Raghavan PR. Metadichol-induced expression of sirtuins 1–7 in somatic and cancer cells. *Med Res Arch.* 2024;12(6). doi:10.18103/mra.v12i6.5371
34. Raghavan PR. Metadichol, a nanolipid emulsion that expresses all 49 nuclear receptors in stem and somatic cells. *Arch Clin Biomed Res.* 2023;7:524-536. doi:10.26502/acbr.50170368
35. Li Y, Shi CX, Mossman KL, et al. Restoration of vitamin C synthesis in transgenic Gulo<sup>-/-</sup> mice by helper-dependent adenovirus-based expression of gulonolactone oxidase. *Hum Gene Ther.* 2008;19(12):1349-1358. doi:10.1089/hum.2008.0106
36. Henriques SF, Dhakan DB, Serra L, et al. Multiple independent L-gulonolactone oxidase gene losses and vitamin C synthesis reacquisition events in non-deuterostomian animal species. *BMC Ecol Evol.* 2019;19(1):86. doi:10.1186/s12862-019-1454-8
37. Álvarez JA, Schofield PK, Malik KM, et al. The evolution of vitamin C biosynthesis and transport in animals. *BMC Ecol Evol.* 2022;22(1):85. doi:10.1186/s12862-022-02040-7
38. Burns JJ, Moltz A, Peyser P. Missing step in guinea pigs required for the biosynthesis of L-ascorbic acid. *Science.* 1956;124(3227):1148-1149. doi:10.1126/science.124.3227.1148
39. Yang H. Conserved or lost: molecular evolution of the key gene GULO in vertebrate vitamin C biosynthesis. *Biochem Genet.* 2013;51(5-6):413-425. doi:10.1007/s10528-013-9586-1

40. Hiller M, et al. Multiple independent L-gulonolactone oxidase (GULO) gene losses in mammals and the genetic basis of vitamin C biosynthesis. *BMC Evol Biol.* 2019;19(1):131. doi:10.1186/s12862-019-1462-5
41. Nishikimi M, Kawai T, Yagi K. Guinea pigs possess a highly mutated gene for L-gulonolactone oxidase, the last enzyme in the vitamin C biosynthetic pathway. *J Biol Chem.* 1992;267(30):21967-21972.
42. Raghavan PR. Umbilical cord cells treatment with Metadichol®: IRS proteins and GLUT4 expression and implications for diabetes. *Stem Cell Res Ther.* 2018;8:429. doi:10.4172/2157-7633.1000429
43. Raghavan PR. Metadichol® induced the expression of neuronal transcription factors in human fibroblast dermal cells. *J Bioinform Syst Biol.* 2023;6:298-311.

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.